236 related articles for article (PubMed ID: 33731798)
1. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
Waghorn PA; Ferreira DS; Erstad DJ; Rotile NJ; Masia R; Jones CM; Tu C; Sojoodi M; Chen YI; Schlerman F; Wellen J; Martinez RVP; Tanabe KK; Fuchs BC; Caravan P
Sci Rep; 2021 Mar; 11(1):6105. PubMed ID: 33731798
[TBL] [Abstract][Full Text] [Related]
2. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis.
Zhou IY; Clavijo Jordan V; Rotile NJ; Akam E; Krishnan S; Arora G; Krishnan H; Slattery H; Warner N; Mercaldo N; Farrar CT; Wellen J; Martinez R; Schlerman F; Tanabe KK; Fuchs BC; Caravan P
Radiology; 2020 Jul; 296(1):67-75. PubMed ID: 32343209
[TBL] [Abstract][Full Text] [Related]
3. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
4. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
Yamada T; Obata A; Kashiwagi Y; Rokugawa T; Matsushima S; Hamada T; Watabe H; Abe K
Magn Reson Imaging; 2016 Jul; 34(6):724-729. PubMed ID: 26979540
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
[TBL] [Abstract][Full Text] [Related]
6. Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study.
Bastati N; Perkonigg M; Sobotka D; Poetter-Lang S; Fragner R; Beer A; Messner A; Watzenboeck M; Pochepnia S; Kittinger J; Herold A; Kristic A; Hodge JC; Traussnig S; Trauner M; Ba-Ssalamah A; Langs G
Eur Radiol; 2023 Nov; 33(11):7729-7743. PubMed ID: 37358613
[TBL] [Abstract][Full Text] [Related]
7. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis.
Tang H; Li J; Zinker B; Boehm S; Mauer A; Rex-Rabe S; Glaser KJ; Fronheiser M; Bradstreet T; Nakao Y; Petrone T; Pena A; Villano M; Chow P; Malhi H; Charles ED; Hayes W; Ehman RL; Du S; Yin M
J Magn Reson Imaging; 2022 Sep; 56(3):712-724. PubMed ID: 35092323
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
10. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by
Rokugawa T; Konishi H; Ito M; Iimori H; Nagai R; Shimosegawa E; Hatazawa J; Abe K
EJNMMI Res; 2018 May; 8(1):40. PubMed ID: 29855729
[TBL] [Abstract][Full Text] [Related]
12. The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.
Akai H; Kiryu S; Ohta Y; Yasaka K; Nakano Y; Inoue Y; Ohtomo K
Magn Reson Imaging; 2017 May; 38():123-128. PubMed ID: 28062263
[TBL] [Abstract][Full Text] [Related]
13. Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats.
Okada M; Katsube T; Kumano S; Kagawa Y; Araki T; Tsuda N; Okuaki T; Imaoka I; Tanigawa N; Ishii K; Murakami T
Acta Radiol; 2011 Jul; 52(6):658-64. PubMed ID: 21498305
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
15. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
[TBL] [Abstract][Full Text] [Related]
17. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
18. Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease.
Pulli B; Wojtkiewicz G; Iwamoto Y; Ali M; Zeller MW; Bure L; Wang C; Choi Y; Masia R; Guimaraes AR; Corey KE; Chen JW
Radiology; 2017 Aug; 284(2):390-400. PubMed ID: 28358240
[TBL] [Abstract][Full Text] [Related]
19. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
20. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
